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Abstract
Objectives—To assess the proportion of patients lost to programme (died, lost to follow-up,
transferred-out) between HIV diagnosis and start of antiretroviral therapy (ART) in sub-Saharan
Africa, and determine factors associated with loss to programme.
Methods—Systematic review and meta-analysis. We searched PubMed and EMBASE databases
for studies in adults. Outcomes were the percentage of patients dying before starting ART, the
percentage lost to follow-up, the percentage with a CD4 cell count, the distribution of first CD4
counts and the percentage of eligible patients starting ART. Data were combined using random-
effects meta-analysis.
Results—29 studies from sub-Saharan Africa including 148,912 patients were analysed. 6
studies covered the whole period from HIV diagnosis to ART start. Meta-analysis of these studies
showed that of 100 patients with a positive HIV test, 72 (95% CI 60–84) had a CD4 cell count
measured, 40 (95% CI 26–55) were eligible for ART and 25 (95% CI 13–37) started ART. There
was substantial heterogeneity between studies (p<0.0001). Median CD4 cell count at presentation
ranged from 154 cells/μl to 274 cells/μl. Patients eligible for ART were less likely to become lost
to programme (25% versus 54%, p<0.0001) but eligible patients were more likely to die (11%
versus 5%, p<0.0001) than ineligible patients. Loss to programme was higher in men, in patients
with low CD4 cell counts and low socio-economic status, and in recent time periods.
Conclusions—Monitoring and care in the pre-ART time period needs improvement, with
greater emphasis on patients not yet eligible for ART.
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Introduction
Attrition of HIV infected patients in care before starting antiretroviral therapy (ART) is high
in low-income settings (Amuron et al. 2009, Bassett et al. 2009). However, much research
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has focused on clinical outcomes of ART, while few studies have analysed loss to
programme (i.e. due to mortality, loss to follow-up or transfer-out to another site) between
HIV testing and ART initiation. Clinical documentation is often poor or non-existent during
this time period. Healthcare systems are overloaded, testing might take place at a different
site than the provision of ART, and patients ineligible for ART are less sick and do not
require monitoring of ART-related side effects. A recent systematic review showed
substantial variation in loss to programme across sites, but did not distinguish between loss
to follow-up, mortality and transfer-out (Rosen & Fox 2011). Only two studies covered the
whole time period from diagnosis of HIV infection to ART initiation (Kranzer et al. 2010,
Tayler-Smith et al. 2010), and predictors of loss to programme were not explored.
Despite the fact that ART coverage in sub-Saharan Africa has increased substantially in
recent years, and had reached 6.6 million people by the end of 2010, approximately 9
million people remain untreated (WHO 2011). The majority of the patients who start ART
do so too late with low CD4 cell counts and opportunistic infections (Keiser et al. 2008,
Fairall et al. 2008, Kigozi et al. 2009). As a result, mortality in the first few months after
therapy start is also high (May et al. 2010, Braitstein et al. 2006).
If the reasons for patient attrition between diagnosis and beginning of ART were known,
programmes could plan more efficiently and better allocate their resources. ART coverage
would be increased, and early mortality on ART would be reduced. Our goal was to
ascertain why patients are lost to programme before they begin ART. We therefore
performed a systematic review to determine the magnitude and predictors of mortality, loss
to follow-up and transfer-out between HIV diagnosis and start of antiretro-viral therapy in
sub-Saharan Africa.
Methods
Data sources
We searched PubMed and EMBASE databases on August 9th 2011, limiting the search to
studies in humans, studies from sub-Saharan Africa and to English-language publications.
We also limited the search to studies that were published after 2001, because ART scale up
in resource-limited settings began in 2002 (Keiser et al. 2008, Gilks et al. 2006). We used
both free text words and Medical Subject Headings (MeSH) and a combination of the
following words and their variations: antiretroviral agents, therapeutic use, pre treatment,
pre-ART, prior to treatment, eligibility, loss to care and loss to follow-up. We examined the
references of all included studies. Further details of the search strategy are given in the web
appendix.
Study selection
We included all studies that reported on numbers of participants followed between HIV
diagnosis and start of ART, including studies that did not cover the entire period. We
excluded studies on children and on the prevention of mother to child transmission
(PMTCT). We also excluded qualitative studies and reports from national programmes.
Studies that reported on specific topics that were not the primary area of interest (i.e.
modelling studies without primary data, studies on drug resistance, adherence or drug
interactions, cancer-specific studies or studies on pre-ART HIV transmission) were also
excluded. We used no other selection criteria. Two reviewers (CM, OK) independently
assessed the eligibility of articles and abstracts. Discrepancies were resolved by consensus.
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Data extraction
To minimise transcription errors, we used a double entry system to enter data from each
publication into a standardised extraction sheet. The following data were extracted:
eligibility criteria of participants, the characteristics of the programme (setting, location,
country), characteristics of participants (age, gender and CD4 cell count at different time
points), eligibility criteria for ART start, methods for tracing patients lost to follow-up and
the number of patients alive and lost to programme (i.e. lost to follow-up, transferred out
and dead) at different time points. We selected four time points: (i) HIV testing, (ii) CD4
testing with eligibility assessment for ART, (iii) becoming eligible for ART and (iv) start of
ART. These defined three time periods: Stage 1 (HIV testing to CD4 testing), Stage 2 (CD4
testing to ART eligibility) and Stage 3 (ART eligibility to ART start). We extracted loss to
programme, mortality, loss to follow-up and transfer-out at each stage before the initiation
of ART. In addition we extracted the length of time between these time points and mortality
rates in the different stages. Further we also extracted predictors for loss to programme,
mortality and loss to follow-up between HIV and CD4 testing and between meeting
eligibility criteria for ART and ART start. We recorded if there was a significant (p<0.05)
positive or negative association or if there was no significant association. Discrepancies
were resolved by consensus. Data were entered into an EpiData database (version 3.1.).
Statistical analysis
We calculated the percentage of people who reached each of the four time points, and
combined data from relevant studies using random-effects meta-analysis on the logit scale.
Combined estimates were transformed back to percentages. Because results were
heterogeneous, we both calculated approximate prediction intervals (PrI) based on the whole
random-effects distribution, and traditional 95% confidence intervals (CI) around the mean
of the distribution. PrI predict the likely mean percentages in new studies and are the most
sensible way to summarize the results of heterogeneous studies (Higgins et al. 2003). We
examined sources of heterogeneity using meta-regression for treatment-eligible patients
starting ART (stage 3; the only stage for which enough estimates were available). We
considered the following study characteristics: country (South Africa versus others); degree
of urbanisation (rural, urban, semi-urban); mode of entry into programme (voluntary
counselling and testing, provider initiated counselling and testing, entry through
Tuberculosis (TB) or sexually transmitted disease clinic); programme costs (free versus fee
for service); ART eligibility criteria (≤200 versus >200 cells/μl); age (median age at
baseline); gender (percentage female at baseline); and study period (1.1.2001–31.12.2003,
1.1.2004–31.12.2006, ≥1.1.2007). Data were analysed using STATA version 11.2
(StataCorp, Texas, USA).
Results
Study characteristics
We identified 81 potentially eligible full text articles out of 2,122 identified studies, based
on titles and abstracts. After screening the full text articles, we included 29 studies of
148,912 treatment naïve patients. 25 studies were included in the meta-analysis. Four studies
were excluded because they reported on the same study population and time period as
another article that was published later (Kaplan et al. 2008, Larson et al. 2010a, Lawn et al.
2005, Losina et al. 2010). The selection of the studies is shown in detail in a flowchart in the
web appendix (Figure S1).
Table 1 summarises the characteristics of the 29 studies included in our review. The
majority (n=16) were single site studies of public-sector ART programmes; 14 were
performed in South Africa. 22 studies included patients from the general population and 11
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were performed in urban sites only. 10 studies reported on ART eligible participants, 15 on
eligible and not yet eligible participants and 2 only on patients not yet eligible for ART.
Eligibility criteria for ART differed between studies. A CD4 threshold of 200 cells/μl was
most commonly used (n=18). Other CD4 thresholds were 250 (n=4) and 300 cells/μl (n=1).
Two studies did not report on eligibility. The definition of LTFU also varied: “missing
appointments for more than 1 month” or “no visit at the clinic for 6 or 12 months” was used
in several studies (Table 1). Phone calls, home visits or linkage to the death registry were
used to ascertain deaths among patients lost to follow-up.
Figure 1 shows the number of studies that reported on different time periods between HIV
diagnosis and ART start. Six studies, conducted in four different countries covered the
whole time period (Bassett et al. 2010, Ingle et al. 2010, Kranzer et al. 2010, Micek et al.
2009, Tayler-Smith et al. 2010, Kohler et al. 2011) from HIV testing to start of ART. Most
studies provided information for the time between ART eligibility and ART start (21
studies, 18 included in meta-analysis). Only a few studies reported on outcomes of patients
without CD4 cell counts and on outcomes of patients not yet eligible for ART.
Meta-analyses
Six studies covering period from HIV diagnosis to ART start (stages 1 to 3)—
Figure 2 summarizes the meta-analyses of the six studies that provided information on the
period spanning HIV infection to start of ART. Of 100 patients who tested positive for HIV,
72 (95% CI 60–84) patients had a CD4 cell count measured, 40 (95% CI 26–55) were
eligible for ART and 25 (95% CI 13–37) started ART.
Stage 1: From HIV to CD4 testing: CD4 cell count was measured in 77.6% (95% CI 71.0–
84.2) of patients, with substantial between-study heterogeneity (I2=99.9%, P-value
<0.0001). The median time from HIV testing to the first CD4 cell count was 56 days in
Losina et al and 60 days in Micek et al. Loubiere et al reported that 56.8% of patients had
their CD4 cell count measured within 30 days of the HIV test, and Larson et al (2010a)
reported that CD4 cell counts were measured on the same day that the HIV test was
administered. Kranzer et al was the only study assessing the different modes of entry into
care during this stage: The median time was between 2 and 3 days, regardless of whether the
patients entered via voluntary counselling and testing, via antenatal care or from a TB or
sexually transmitted infections (STI) clinic.
Stage 2: Assessment of eligibility for ART: The median CD4 cell count at presentation to
the clinic ranged from 154 (IQR 57–302) to 274 (IQR 139–435) cells/μl in the 6 studies
where this information was provided (Table 1). The percentage of patients with a CD4 cell
count who were eligible for ART was 56.5 % (95% CI 49.3–63.6), again with substantial
between-study heterogeneity (I2=99.5%, P-value <0.0001).
Stage 3: From eligibility to start of ART: Eighteen studies reported the percentage of
patients who started ART after becoming eligible: the overall estimate was 62.9% (95% CI
55.2–70.7); I2=99.7%, heterogeneity P-value <0.0001. In meta-regression the estimated
percentage of patients starting ART increased from 44% to 81% as the percentage of women
increased from 50% to 75% and no other factors were associated with the percentage of
patients starting ART. Of note, two programmes in which very few eligible patients started
ART (Murphy et al. 2010, Zachariah et al. 2006) included only patients who had entered the
HIV programme from a TB clinic. 5 of the 25 studies reported on the median duration from
becoming eligible to starting ART. The median duration was 22 days (McGrath et al. 2010),
34 days (Lawn et al. 2006), 83 days (Murphy et al. 2010), 95 days (Ingle et al. 2010) and
Mugglin et al. Page 4
Trop Med Int Health. Author manuscript; available in PMC 2014 January 20.
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
108 days (Bassett et al. 2009). Figure S2 shows the forest plots from the meta-analyses of all
three stages.
Pre-ART loss to programme, loss to follow-up, mortality and transfer-out—
Figure 3 shows forest plots of overall loss to programme, loss to follow-up and mortality by
ART eligibility. Among eligible patients 24.6% (95% CI 18.8–30.3) were lost to programme
(Figure 3A) whereas among ineligible patients 54.2% (95% CI 42.8–72.0) were (Figure 3B).
Mortality before treatment initiation in eligible patients was 10.8 % (95% CI 4.6–17.0;
Figure 3C), with rates ranging from 1.6 to 53.2 per 100 person-years (Table 1). In 3 studies
reporting on patients not yet eligible for ART, 4.8% (95% CI 0–13.0) died (Figure 3D). For
loss to follow-up, the corresponding numbers were 13.2% (95% CI 9.3–17.1, Figure 3E) in
eligible patients and 57.3% (95%CI 34.3–80.2, Figure 3F) in ineligible patients. Data on
transfers out were reported in only few studies: overall 5.5% (95% CI 0–13.3%) of patients
were transferred before ART initiation (2 studies). Transfers prior to ART initiation were
more common in ART eligible patients: 20.1% (95% CI 7.6–32.6%), based on 4 studies.
Predictors of mortality, loss to programme, CD4 cell count determination and ART
initiation
These results are summarized in Tables S1 and S2. Briefly, men were more likely to be lost
to programme and less likely to start ART than women. The same association was described
for patients with a lower socioeconomic status and lower CD4 count, and for later time
periods. Conversely, older age and less advanced clinical stage were associated with start of
ART. Only a few studies analysed predictors of mortality and of having a CD4 cell count
determined.
Discussion
This systematic review and meta-analysis, based on more than 140,000 patients from 12
countries in sub-Saharan Africa, shows that pre-ART attrition is high: only about 25 of 100
newly diagnosed patients with HIV started ART even though in most clinics the median
CD4 cell count at presentation was below 200 cells/μl. Loss to programme was twice as
high in patients not yet eligible for ART as in patients eligible for ART, whereas mortality
was more than twice as high in eligible patients compared to ineligible patients. The few
studies that reported on predictors of loss to programme showed higher rates of loss in men,
in patients with low CD4 cell counts, in patients of low socio-economic status, and in recent
time periods.
Many patients with a positive HIV test were lost before eligibility for ART was determined.
This is illustrated by Micek et al. (2009), most of whose patients had to be referred to the
ART clinic for CD4 measurements: immune status was assessed in fewer than half of the
patients. Two recently published studies suggested that point-of-care CD4 tests could
improve the linkage to care. Faal et al (2011) found that providing the CD4 results at the
time of HIV testing increased ART initiation rates, and in Mozambique Jani et al. (2011)
showed that after the introduction of a point-of-care CD4 test, the proportion of patients lost
to follow-up dropped from 57% to 21%. In some studies CD4 counts were measured more
than two months after the HIV test and in only one site CD4 testing was done on the same
day as the HIV test (Larson et al. 2010a). Unfortunately the latter study did not evaluate pre-
ART loss to programme and it is unclear whether this approach led to a higher proportion of
patients starting ART.
The design of some studies may explain why the proportion of patients with a CD4 cell
count differed (Larson et al. 2010b, Kohler et al. 2011, Pepper et al. 2011). Larson et al
distinguished between measured and completed CD4 cell count testing: 84.6% of the HIV
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positive patients had a CD4 cell count measured but only 53.1% of the eligible, and 45.7%
of the not yet eligible patients picked up the results. Pepper et al included only HIV positive
patients on TB treatment; in this integrated TB/HIV clinic the majority of patients had a pre-
ART CD4 test done as part of the routine follow-up to determine eligibility for ART. In
Kohler et al’s study in 2011, the introduction of free Cotrimoxazole (CTX) prophylaxis
improved pre-ART retention and CTX provision may therefore be associated with a larger
proportion of patients with a CD4 cell count. Different study locations, patient management
strategies and local guidelines are other possible sources of heterogeneity. Predictors of
receiving a CD4 cell count were also investigated in a recent study by a mobile HIV testing
unit in South Africa. Low CD4 cell count, female sex, and the availability of a phone
correlated with reception of test results. Patients with the lowest CD4 cell counts were most
likely to be linked to facility-based HIV care (Govindasamy et al. 2011).
It is worrisome that few patients started ART despite low CD4 cell counts at presentation.
Although ART eligibility criteria varied between studies, the majority used a CD4 threshold
of 200 cells/μl. With the new threshold of 350 cells/μl or a universal ‘test and treat’
approach, the number of ART eligible patients will increase substantially. It is unclear what
the significance of our results for a ‘test and treat’ strategy is. Although all HIV patients
would qualify for ART, the high loss to follow-up rate among ineligible patients may also
demonstrate how difficult it is to retain asymptomatic patients in care. Only few studies
evaluated the factors associated with loss to follow-up and, interestingly, these factors were
previously described as predictors of LTFU in patients on ART (Maskew et al. 2007,
Ekouevi et al. 2010, Makombe et al. 2007, Boyles et al. 2011). The high LTFU rate in
younger men may have psychosocial and structural origins (Cornell et al. 2009) while the
increase over time may be due to an overburdened health system as the number of patients
continues to increase.
This systematic review has several limitations. First, in all meta-analyses between-study
heterogeneity was substantial. Second, differing definitions of loss to follow-up and ART
eligibility criteria made comparing the studies difficult. Patients lost to follow-up may re-
enter the health system later, when they are much sicker. Also, many studies did not
describe the clinical and immunological criteria for ART eligibility in detail. Third, the
number of included studies and countries was limited and only few studies covered the
whole pre-ART period from HIV diagnosis to ART initiation; generalizability may therefore
also be limited. Nor could we determine the point at which LTFU and mortality rates were
highest. Fourth, only a few studies reported on the proportion of patients transferred out. In
other studies these patients may have been assumed lost to follow-up, thus underestimating
linkage to care. Fifth and finally, the reasons patients are lost to care are poorly reported and
tracing these patients is rarely described. Mortality is generally expected to be
underestimated because patients lost to follow-up are at higher risk of death (Brinkhof et al.
2009).
Our findings illustrate the urgent need to find ways to improve linkage between HIV testing
and care in low-income countries. Possible interventions to maximize retention in care
include (i) making point-of-care CD4 cell counts available at HIV testing facilities to
minimize losses between HIV diagnosis, CD4 count and pick-up of the result; (ii) reduce the
number of required visits before ART initiation and thus the financial burden on patients;
(iii) keep the time period between ART eligibility and initiation as short as possible without
undermining ART counselling, (iv) motivate ineligible patients to return in regular intervals
and (v) introduce health information systems to better monitor the pre-ART period and
patient movement and trace patients not returning to re-assess treatment eligibility.
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In conclusion, this systematic review shows that linkage from HIV diagnosis to HIV care is
poor in resource limited settings. In order to achieve satisfying ART coverage, monitoring of
pre-ART patients needs to be improved and strategies to increase retention in care need to be
implemented.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Routes from HIV testing to start of antiretroviral therapy. Shaded boxes show the different
pre-ART care points, and shaded circles show the number of studies included in the
systematic review (number of studies included in the meta-analysis in parentheses) at each
of these stages. The three areas (number 1 to 3) represent the different stages in the cascade
which are described in more detail in the text (i.e. stage 1: From HIV to CD4 testing; stage
2: eligibility assessment; stage 3: from eligibility to start of ART). #Completed: the patient
was informed about the CD4 test result or the CD4 test was done within a certain time
period after the HIV test; *LTP: loss to programme
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Figure 2.
Percentage of HIV positive patients completing different stages between testing positive for
HIV infection and start of antiretroviral therapy (ART). Results from meta-analysis of six
studies covering the period from HIV testing to start of ART. The six studies include 58,746
patients (Bassett et al. 2010, Ingle et al. 2010, Kohler et al. 2011, Kranzer et al. 2010, Micek
et al. 2009, Tayler-Smith et al. 2010).
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Figure 3.
Meta-analysis of loss to programme, mortality and loss to follow-up during the pre-ART
phase, according to whether patients were or were not eligible for ART. Panel A/B:
Percentage of ART eligible/ineligible patients becoming loss to programme (LTP) before
ART start. LTP includes mortality, loss to follow-up, transfer out and alive but not in
programme. Panel C/D: Percentage of ART eligible/ineligible patients dying before ART
start. Panel E/F: Percentage of ART eligible/ineligible patients becoming lost to follow-up
before ART start.
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